Emerging perspectives in the combined application of SGLT2i and GLP-1 RAs for CKD and DKD, highlighting advances in biomarker discovery, personalized treatment strategies, and novel therapeutic indications are depicted in Figure 6. The gene discussed is GCG; the disease is diabetic kidney disease.